Allogene Stock: If MRD Holds, This Becomes A Completely Different Company (NASDAQ:ALLO)
· seekingalpha.com
Allogene Therapeutics maintains a $423.6M cash balance, disciplined cost controls, and a runway into 2029. Read why I rate ALLO stock a Buy.
Allogene Therapeutics ( ALLO ) seems to be setting up as a classic asymmetric biotech play going into 2H26. I think the market is still anchoring the stock to c...